Agnes Bosch

TL;DR: SGLT-2 inhibition with dapagliflozin resulted in a significant decrease in tissue sodium content of the skin after 6 weeks, which point to a decrease of total sodium content in patients with type 2 diabetes prone to cardiovascular complications, that might be mitigated by SGLT -2 inhibition.

TL;DR: The analysis suggests that empagliflozin exerts, at least to some extent, its beneficial vascular effects via anti-inflammatory mechanisms in type 2 diabetes mellitus patients.

TL;DR: Patients with hypertension stage 1 or 2 showed retinal capillary rarefaction in comparison to healthy normotensive subjects, indicating a lower level of retinalcapillary density in hypertensive patients, especially in those with long time hypertension.

TL;DR: In this paper, the SGLT 2 inhibition with empagliflozin increases ketone bodies in patients with stable CHF and whether such an increase impairs BP and vascular function.

TL;DR: Patients with moderately severe CKD show retinal signs of end-organ damage indicated by an increased wall-to-lumen ratio and capillary rarefaction, as measured by scanning laser Doppler Flowmetry.